Eli Lilly's IL-23 inhibitor mirikizumab shows late-stage promise in ulcerative colitis — but AbbVie's Skyrizi looms
As one of the key drivers in Eli Lilly’s mission to revamp its pipeline, IL-23 inhibitor mirikizumab has come out swinging against potential competitor Cosentyx and has looked to score a big win as the first ulcerative colitis therapy in its class. Now, that big approval is one step closer.
In a 12-week Phase III induction study dubbed LUCENT-1, Lilly’s mirikizumab beat out placebo at controlling or resolving ulcerative colitis patients’ symptoms, the drugmaker said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.